natgillin/translations-raw huggingface dataset:
In certain embodiments, the present invention provides a pharmaceutical composition suitable for topical administration to an ocular surface of an individual in need a pharmaceutically effective concentration of a PRG4 inducing compound, an optional mucoadhesive agent, and, optionally, PRG4 suspended in an ophthalmically acceptable balanced salt solution, and in combination with one or more ophthalmically acceptable agents. The ophthalmically acceptable agents can be selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, and emollient. As used herein, the term “effective concentration or amount” or “therapeutically effective concentration or amount” is intended to mean a nontoxic but sufficient concentration or amount of a PRG4 inducing compound, the PRG4, or the other therapeutic agents to provide the desired therapeutic effects. 
Farmaceutski oblik za uporabu u liječenju vodene ili isparavajuće bolesti suhog oka, stanja koja su povezana s ili uzrokuju vodenu ili isparavajuću bolest suhog oka, ili s njima povezanih simptoma, u pojedinca, oblik je prikladan za topikalnu primjenu na površinu oka, sadrži terapijski učinkovitu koncentraciju PRG4 suspendiranog u oftalmički prikladnoj uravnoteženoj fiziološkoj otopini. Farmaceutski oblik za uporabu prema zahtjevu 1, sadrži jedan ili više oftalmički prikladnih sredstava izabranih iz skupine koja obuhvaća oftalmički prikladno sredstvo za ublažavanje, oftalmički prikladnu pomoćnu tvar, oftalmički prikladan adstringent, oftalmički prikladan vazokonstriktor, oftalmički prikladan elektrolit, oftalmički prikladan natrijev hijaluronat ili hijaluronsku kiselinu, oftalmički prikladan površinski aktivan fosfolipid 1 oftalmički prikladan emolijens.
The compound for use according to claim 1, wherein the method comprises determining the presence of H-Ras mutation in a sample from said subject. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu metoda sadrži utvrđivanje pristunosti H-Ras mutacije u uzorku uzetom od navedenog subjekta.
The mixture of claim 1 wherein the L-amino acid is selected from the group consisting of L-alanine, L-valine, L-proline, L-leucine, L-cysteine, L-threonine, L-glutamine, L-asparagine, L-phenylalanine and analogues thereof. 
Smjesa sukladno zahtjevu 1, naznačeno time, da je L-aminokiselina odabrana iz skupine koju čini L-alanin, L-valin, L-prolin, L-leucin, L-cistein, L-treonin, L-glutamin, L-asparagin, L-fenilalanin i njihovih analog.
decoding, in a receiver of a device, the payload data transmitted at the higher data rate indicated within the frame information portion, using a clock signal recovered from the data sent at a higher data rate. 
dekodiranje, u jednom prijamniku od jednog uređaja, skupova korisničkih informacija (36) koji su preneseni uz veću podatkovnu brzinu, prikazanom unutar odsjeka informacijskog okvira (34), korištenjem taktnog signala koji se obnovljen dobio iz podataka koji su poslani uz veću podatkovnu brzinu.
A method for inhibiting VR1 function in a cell comprising contacting a cell, capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 or claim 10. 
Metoda inhibicije funkcije VRI u stanici in vitro koja sadrži dolaženje u kontakt sa stanicom, koja može eksprimirati VR1 s učinkovitom količinom spoja ili farmaceutski prihvatljive soli spoja prema zahtjevu 1 ili zahtjevu 20.
The method as claimed in claim 2, wherein the order of the beverage variants in the job list is changeable by the user. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što korisnik može promijeniti redoslijed varijanti napitaka u spisku zadataka, osobito pomicanjem grafika.
The inventors have discovered 2 crystalline forms of the hydrogen succinate salt of Compound I (named alpha and beta). 
Sol sukcinata prema zahijevu 1, a to je vodik sukcinatna sol spoja formule (I).
A method of passing smoke and/or mist through a network of conduits of a deluge fire extinguishing system for testing openness of the deluge fire extinguishing system, wherein the smoke and/or mist comprises an optical smoke density of at least 1 per meter and/or wherein a flow of the smoke and/or mist being inserted in the deluge fire extinguishing system is chosen such that a speed of the smoke and/or mist exiting from spray heads of the deluge fire extinguishing system is at least 10 meters per second. 
Uporaba dima i/ili magle u mreži cijevi (18A-E) poželjno otvorenog ili deluge (gašenje vodom i/ili pjenom) sustava za gašenje požara radi testiranja otvorenosti sustava za gašenje požara, pri čemu je dim optičke gustoće od barem 1 po metru i/ili gdje je u tijek dima umetnut u sustav za gašenje požara odabran tako, da brzina dima koji izlazi iz štrcaljki (17A-E) sustava je barem 10 metara po sekundi.
is hydrogen, C1 to C12 alkyl, phenyl unsubstituted or substituted by C1 to C12 alkyl or COR6 acyl group; R6 being hydrogen, C1 to C12 straight chain or branched alkyl, phenyl or benzoyl, respectively unsubstituted or substituted by C1 to C12 alkyl, or any group leading to hydroxyl upon biological metabolization or chemical deprotection, particularly an ester, ether, acetale, carbonate, carbamate, phosphate, phosphonate, ketal, sulfate, or sulfonate; and salts thereof, for use in a medical treatment as angiogenesis inhibitor. The compound defined by the formula 1 wherein 
je vodik, C1 do C12 alkil, fenil koji nije supstituiran ili je supstituiran s C1 do C12 alkilnom ili COR6 acilnom skupinom; R6 je vodik, C1 do C12 nerazgranati ili razgranati alkil, fenil ili benzoil, koji odgovarajuće nije supstituiran ili je supstituiran s C1 do C12 alkilnom, ili bilo kojom skupinom koja se pretvara u hidroksilnu biološkim metaboliziranjem ili kemijskim uklanjanjem zaštite, osobito estera, etera, acetala, karbonata, karbamata, fosfata, fosfonata, ketala, sulfata ili sulfonata; i njihovih soli, naznačen time što je namijenjen upotrebi u medicinskom liječenju kao inhibitor angiogeneze, gdje je navedeni spoj 4-hidroksitestosteron, ili njegove soli ili esteri.
In said embodiment, pieces of wood for the manufacture of veneer were obtained, wherein a section II as shown in Fig. 11 was separated from the center of a log 50, whereby, in the present embodiment, said log 50 was cleaved into three sections I, II, III. 
U navedenom ostvarenju su komadi od drva za proizvodnju furnira bili dobiveni, pri čemu je sekcija II, kao Stoje prikazani na slici 11, bila je odvojena od sredine debla 50, i pri čemu je, u predmetnom ostvarenju navedeno deblo 50 bilo iscijepano na tri sekcije [, TI, III.
The CD37-specific binding protein according to claim 1, 2, or 3 wherein the binding protein has a binding affinity for human CD37 of about 0.5 nM to about 10 nM. 
Humanizirani CD37-specifični vezni protein iz bilo kojeg od patentnih zahtjeva 1 do 8, ili sastav iz patentnog zahtjeva 10, za uporabu u liječenju.
The nutrition according to embodiment 1 which is in a ready-to-feed liquid form. 
Hrana prema zahtjevu 1, naznačena time što je u tekućem obliku spremnom za hranjenje.
The IL-18BP subject to the purification process according to the present invention may be glycosylated or non-glycosylated, it may be derived from natural sources, such as urine, or it may preferably be produced recombinantly. 
IL-18BP koji se pročišćava prema procesu iz ovoga izuma može biti glikoliziran ili ne, može biti deriviran iz prirodnih izvora poput mokraće ili može biti dobiven tehnologijom rekombinantne DNA, stoje najpoželjnije.
In a 45th Specific Embodiment, the disclosure provides a method for therapeutically increasing the diameter of an artery or vein in a human subject in need thereof, the method comprising: locally administering to the wall of the artery or vein in the human subject the pharmaceutical composition of the 36th Specific Embodiment in a dose sufficient to increase the diameter of the artery or vein. 
(iv) farmaceutski sastav je primijenjen na zidu krvnog suda pomoću katetera za isporuku lijeka; (b) terapijskog povećanja promjera arterije ili vene kod ljudskog subjekta kojem je to potrebno lokalno primjenjujući farmaceutski sastav na zid arterije ili vene kod ljudskog subjekta;
The oral composition of item 42, wherein the agent for preserving bsh activity comprises inulin, trealose, maltodextran, yeast extract, polyethylene glycol, glycerol, lipid, emulsified fat, a dairy product, glucose, fructose, sucrose, a poly sugar, anhydrobiosis, a polycosanol, polyethlylene glycol (PEG), a plant sterol, a plant stanol or an omega fatty acid. 
(d) agens za očuvanje BSH aktivnosti, opcionalno inulin, trehaloza, maltodekstran, ekstrakt kvasca, polietilen glikol, glicerol, lipid, emulzirana masnoća, dijetni proizvod, glukoza, fruktoza, sukroza, poli šećer, anhidrobioza, polikozanol, polietilenglikol (PEG), biljni sterol, biljni stanol ili omega masna kiselina;
in which R1A and R2 are each as defined above, and this is then reacted in an inert solvent, in the presence of a suitable catalyst and a suitable base, with a compound of the formula (XI) 
(X) gdje R" i R* su svaki kako je gore definirano, te ovo nakon toga reagira u inertnom otapalu, u prisutnosti prikladnog katalizatora i odgovarajuće baze, sa spojem s formulom (XI)
A method for the treatment of infection by HIV or for the treatment of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 4 . 
Spoj prema patentnom zahtjevu 10 za upotrebu u profilaksi ili tretmanu infekcije HIV-om ili za profilaksu, tretman ili odgađanje početka SIDA-e kod subjekta kod kojeg postoji potreba za tim.
is hydrogen, substituted hydrocarbyl, or hydrocarbyl; is 
R.2 je vodik, hidrokarbil ili supstituirani hidrokarbil;
An aqueous composition according to aspect 15, wherein the reactive compound is selected from the group consisting of a redox active compound, a radical building compound, a stabilizing compound and a combination of any thereof. 
Vodeni pripravak sukladno zahtjevima 1 do 8, koja dalje sadrži reaktivni spoj odabrano iz skupine sastavljene od redoks aktivnog spoja, spoj koji tvori radikal, stabilizirajućeg spoja i bilo koje njihove kombinacije.
A method according to any one of claims 1 to 3, wherein the cell is co-transformed with at least two different variants of gene A to be recombined, which are genes A1 and A2, and optionally with at least two different variants of gene B to be recombined, which are genes B1 and B2. 
Metoda u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu se stanice nazivaju kotransformiranima s najmanje dvije različite varijante gena A za rekombinaciju, koji su geni A1 1 A2, i neobavezno s najmanje dvije različite varijante gena B za rekombinaciju, koji su geni B1 i B2.
The compound of claim 2, wherein the compound is: 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što spoj je: 4.
The method of claim 3 wherein R4 and R5 are independently hydrogen, aliphatic or heteroaliphatic. 
[image] naznačen time da R7 je vodik, alifatski ili heteroalifatski ostatak i R8 je alifatski ili heteroalifatski ostatak.
In a particularly preferred embodiment, a second surface of the said sheet or web, opposite to the said imprinted or coated first surface, is approached to or brought into loosely contact with the engraved surface of the body of magnetized composite permanent-magnetic material. 
U posebno poželjnom utjelovljenju, donja površina navedenog lista ili tkanine, koja se nalazi suprotno od navedene otisnute ili premazane gornje površine, približi se ii dovede u labavi kontakt s ugraviranom površinom tijela izrađenog od magnetiziranog kompozitnog permanentno magnetskog materijala.
to form a compound of Formula I, or salt thereof; 
II da se dobije spoj s formulom I, ili njegova sol; i
is a hydrogen atom; a hydroxy group; a straight or branched C1-C6 alkyl group unsubstituted or substituted with a straight or branched C1-C5 alkyl group, a halogen atom, a straight or branched C1-C5 alkoxy group, or a straight or branched C1-C3 thioalkyl group; a halogen atom; a straight or branched C1-C6 alkoxy group unsubstituted or substituted with a straight or branched C1-C5 alkyl group, a halogen atom, a straight or branched C1-C5 alkoxy group, or a straight or branched C1-C3 thioalkyl group; or a straight or branched C1-C4 thioalkyl group unsubstituted or substituted with a straight or branched C1-C5 alkyl group, a halogen atom, a straight or branched C1-C5 alkoxy group, or a straight or branched C1-C3 thioalkyl group; and 
R je atom vodika; hidroksi grupa; ravna ili razgranata C,-C4 alkil grupa nesupstituirana ili supstituirana sa ravnom ili razgranatom Ci-Cs alkil grupom, atomom halogena, ravnom ili razgranatom Ci-Cs alkoksi grupom, ili ravnom ili razgranatom Ci-C3 tioalkil grupom; atom halogena; ravna ili razgranata C;-Cg alkoksi grupa nesupstituirana ili supstituirana sa ravnom ili razgranatom C;-Cs alkil grupom, atomom halogena, ravnom ili razgranatom C,-Cs alkoksi grupom, ili ravnom ili razgranatom C;-C3 tioalkil grupom; ili ravna ili razgranata C;j-C, tioalkil grupa nesupstituirana ili supstituirana sa ravnom ili razgranatom C;-Cs alkil grupom, atomom halogena, ravnom ili razgranatom C;-Cs5 alkoksi grupom, ili ravnom ili razgranatom Cy-C> tioalkil grupom;
The co-crystal of clause 2, wherein the molar ratio of VX-950 and 4-hydroxybenzoic acid is about 1:1. 
NC H4&" | "EH, Bac CH, i 4-hidroksibenzojeve kiseline iznosi otprilike 1:1.
The solution is acidified to pH1 using 6M HCl and the resulting suspension is filtered and dried to yield the titled product. 
Otopinu sc zakiscli na pH 1 upotrebom 6M HCI i dobivenu suspenziju se profiltrira i osuši, čime se dobije naslovni proizvod.
at least one source of a water soluble lithium compound selected from the group comprising inorganic and/or organic salts of lithium, bases of lithium and mixtures thereof, and preferably selected from lithium chloride and/or lithium carbonate and/or lithium hydroxide, in an amount such that the total amount of solubilised lithium in the aqueous preparation is from 1000 to 3000 ppm, calculated relative to the weight of water in the preparation; as a biocidal composition in an aqueous preparation comprising strains of bacteria selected from the group consisting of Methylobacteria and Pseudomonas which are resistant to, tolerant to and/or degrade aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in absence of lithium ions. 
(b) barem jedan izvor u vodi topljivog spoja litija odabran iz skupine koju čine neorganske i/ili organske litijeve hidroksida, u količini tako da je ukupna količina otopljenog litija u vodenom pripravku od 1000 do 3000 ppm, izračunato u odnosu na težinu vode u pripravku; kao biocidnog pripravka u vodenom pripravku koji sadrži sojeve bakterija odabrane iz skupine koju čine Metilobacteria i Pseudomonas koje su rezistentne na, tolerantne na i/ili degradiraju biocide koji oslobađaju aldehid ifili biocide s jednom ili više aldehidnih skupina u odsutnosti litijevih iona.
The use of claim 28, wherein the lung infection is caused by a gram-negative anaerobic bacteria, by a gram-positive bacteria, by a gram-positive anaerobic bacteria, by an acid-fast bacteria or by an atypical bacteria. 
31. Uporaba iz patentnog zahtjeva 28, pri čemu infekciju pluća uzrokuje gramnegativna anaerobna bakterija, uz pomoć gram pozitivnih bakterija.
the lysine at position 9 of the BC loop (SEQ ID NO: 34) is substituted with an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, L, M, N, Q, R, S, T, V, W, and Y; 
lizin na položaju 9 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, D, E, F, G, H, I, L, M, N, Q, R, S, T, V, W te Y;
The compound of para 1 or 12, wherein enantiomeric excess of said compound is at least about 80%. 
Spoj prema zahtjevu 6, naznačen time, da enantiomerni višak navedenog spoja iznosi najmanje oko 80%.
is C1-6alkyl, which is unsubstituted or substituted with 1-6 fluoro, wherein R1 and the hydroxyl group on the ring are attached to the same carbon atom; 
R' je Crsalkil, koji nije supstituiran ili je supstituiran s 1-6 fluora, gdje su R' i hidroksilna skupina na prstenu vezani za isti atom ugljika.
A cancer chemotherapeutic agent according to any of claims 1 to 3, which is a compounding agent. 
Protutumorsko kemoterapijsko sredstvo u skladu s patentnim zahtjevom 1, naznačeno time, da je to kombinacijsko sredstvo.
A modified capsular saccharide comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): 
Modificirani saharid iz kapsule, koji sadrži blokirajuću skupinu na položaju hidroksilne skupine u najmanje 80% monosaharidnih jedinica odgovarajućeg nativnog saharida kapsule, gdje blokirajuća skupina ima formulu (Ia): -O-X-Y
(xiii) blood diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
(xiii) krvnih bolesti, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
a tautomer, or a pharmaceutically acceptable salt thereof, wherein: 
OH ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat, pri čemu:
The method according to claim 1, wherein the fried coated portion has a core temperature of not less than 65°C, preferably not less than 70°C when it is introduced into the freezer. 
Postupak prema patentnom zahtjevu 2, pri čemu ispržena obložena porcija ima temperaturu jezgre ne manju od 70°C kada je uvedena u zamrzivač.
The use of a compound according to any one of claims 1 to 3 for the manufacture of a medicament for the treatment or prevention of neoplastic diseases and immune system disorders. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 3, naznačena time, da je za proizvodnju lijeka za liječenje ili prevenciju neoplastičnih bolesti i poremećaja imunološkog sustava.
the anionic exchange chromatography step is carried out using 1 mL of anionic exchange matrix resin for every 1 mg of GAS carbohydrate; and/or the anionic exchange chromatography step is performed under conditions that allow flow through of the GAS carbohydrate. 
(b) korak anionskoizmjenjivačke kromatografije se provodi uz upotrebu 1 ml smole kao matriksa za anionsku izmjenu za svaki 1 mg GAS ugljikohidrata; i/ili (c) korak amionskoizmjenjivačke kromatografije se provodi u uvjetima koji omogućuju prolaženje GAS ugljikohidrata.
In certain embodiments, the activated acetic acid is acetic anhydride. In certain embodiments, the activated acetic acid is a thioester of acetic acid. In certain embodiments, the molar ratio of the activated acetic acid versus 2-amino-6-nitrobenzoic acid in step (a) (i.e., reacting 2-amino-6-nitrobenzoic acid with acetic anhydride in a solvent to form 2-methyl-5-nitro-4H-benzo[d][1,3]oxazin-4-one) is ranging from about 1 to about 10. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 11 do 13, naznačen time što dodatno uključuje korak reakcije 2-amino-6-nitrobenzojeve kiseline s aktiviranom octenom kiselinom u otapalu kako bi se dobilo 2-metil-5-nitro- 4H-benzol[d][1,3]oksazin-4-on, prije reakcije 2-metil-5-nitro-4H-benzol[d][1,3]oksazin-4-ona s 3-aminopiperidin2,6-dionom, ili njegovom solju; po mogućnosti gdje je aktivirana octena kiselina acetil-klorid ili acetanhidrid.
the selection of the input channel carrying the frequency offset estimate signal with the communication signal, from a first input channel for analogue communication signals and a second input channel for digital communication signals; and 
- < odabir ulaznog kanala koji prenosi očekivani signal odlazne frekvencije s komunikacijskim signalom, od prvog ulaznog kanala za analogne komunikacijske signalc i od drugog ulaznog kanala za digitalne komunikacijske signale; i
The anti-FcRH5 antibody of any one of claims 1-5, wherein the anti-FcRH5 antibody has one or more of the following characteristics: (a) cross-reactive with full-length human and cyno FcRH5, (b) does not cross-react with FcRH1, FcRH2, FcRH3, and/or FcRH4, (c) binds to endogenous FcRH5, and (d) does not cross-react with FcRH5a. 
6. - Protutijelo anti-FcRH5 prema bilo kojem od zahtjeva 1 do 5, naznačeno time, da protutijelo anti-FcRH5 ima jednu ili više od sljedećih karakteristika: (a) jest unakrsno-reaktivno s ljudskim i psećim FcRH5 pune duljine, (b) nije unakrsno-reaktivno s FCRH1, FcRH2, FcRH3 i/ili FeRH4, (c) veže se na endogeni FcRHS, i (d) nije unakrsnoreaktivno s FcRH5Sa.
The process of claim 1, wherein said PSA adsorbs at a temperature of at least 150°C and a pressure of at least 5516 kPa (800 psia). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni PSA adsorbira na temperaturi od najmanje 150 *C i pod tlakom od najmanje 5516 kPa (800 ps1a).
A spray dispenser according to claim 9, wherein the dispensing assembly comprises the closure. 
Raspršivač sukladno zahtjevu 9, pri čemu sklop za točenje sadrži sredstvo (106) za zatvaranje.
The mooring buoy of claim 1, wherein the RF communication device is configured to receive the vessel ID associated with the marine vessel from a vessel RF communication device located on the marine vessel. 
Plutača za privez (101) prema zahtjevu 1, naznačena time što je RF komunikacijski uređaj (403) postavljen da prima ID plovila koji je povezan s plovilom (1004) iz brodskog RF komunikacijskog uređaja koji se nalazi na plovilu (1004).
According to an embodiment of the invention the lozenge provides for controlled release of the active agent. 
Prema varijanti prema izumu tableta osigurava kontrolirano oslobađanje aktivnog sredstva.
Alternatively, the invention provides anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having a molar ratio of chloride to anamorelin less than or equal to 1:1, such as from 0.9 to 1.0 or 0.99. 
Izolirani čvrsti oblik anamorelin monohidroklorida, naznačen time što navedeni anamorelin monohidroklorid ima molarni odnos klorida:anamorelina od 0.9 do 0.99, i sadrži rezidualni sadržaj organskog otapala koji je manji od 5000 ppm.
Powders, materials for spreading and dusts can be prepared by mixing or concomitantly grinding the synergistic herbicidal mixture or the individual active ingredients with a solid carrier. 
Prašci, materijali za razvijavanje i prašci mogu biti pripremljeni mješanjem ili zajedničkim mljevenjem sinergističke herbicidne smjese ili pojedinačnih aktivnih sastojaka sa čvrstim nosačem.
SUMMARY OF THE INVENTION In order to better address one or more of the foregoing desires, the invention, in one aspect, presents a method for the removal of urea dust from the off-gas of a finishing section of a urea production plant, the method comprising subjecting the off-gas to quenching with water, particularly so as to produce quenched off-gas having a temperature below about 45° C., and subjecting the quenched off-gas to scrubbing using at least one venturi scrubber. 
Postupak za uklanjanje prašine uree iz sagorjelog plina iz dijela za krute čestice postrojenja za proizvodnju uree, pri čemu taj postupak obuhvaća podvrgavanje sagorjelog plina hlađenju vodom tako da se proizvede brzo ohlađeni sagorjeli plin, i podvrgavanje toga ohlađenog sagorjelog plina pročišćavanju korištenjem najmanje jednog venturinskog pročistača, pri čemu se brzo hlađenje odvija prije nego što sagorjeli plin uđe u venturinski pročistač, i sadrži dodavanje tekućine za pročišćavanje u venturinski pročistač na njegovom grlu ili na ulazu u njegov dio za konvergenciju tako da tekućina za pročišćavanje ulazi u ohlađeni sagorjeli plin.
The circulation loop flow was set at 583 l·h−1kg−1during 30 min. at a temperature of 60° C. 
Cirkulacijski protok je bio podešen na 583 1.h'.kg"' tijekom 30 min, kod temperature od 60 *C.
Moreover, the amount of fat can be reduced in ice cream containing the sugar replacement composition according to the invention. 
Štoviše, pripravom sladoleda sa sastavinom prema ovom izumu koja zamjenjuje šećer, može se smanjiti i sadržaj masnoća u sladoledu.